Alkermes vs Amneal Pharmaceuticals
Amneal Pharmaceuticals reported revenue of $3.0 billion in fiscal 2025, 2.0 times Alkermes' $1.5 billion in fiscal 2025. Alkermes' revenue fell 5.2% in its latest year, and Amneal Pharmaceuticals' grew 8.1%. Alkermes had an operating margin of 17.2%, against 13.1% at Amneal Pharmaceuticals. Free cash flow was $480 million at Alkermes and $270 million at Amneal Pharmaceuticals.
Side by side
| Alkermes | Amneal Pharmaceuticals | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $1.5B | $3.0B |
| Revenue growth | −5.2% | 8.1% |
| Revenue growth a year, last 5 years | 7.3% | 8.7% |
| Gross margin | 86.7% | 36.9% |
| Operating margin | 17.2% | 13.1% |
| Net margin | 16.4% | 2.4% |
| Free cash flow | $480M | $270M |
| Free cash flow margin | 32.5% | 8.9% |
| Return on capital | — | 16.1% |
| Net debt to EBITDA | — | 3.8x |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | −0.3% | 5.1% |
| Last close | $44.44 | $21.02 |
| P/E at the last close | 116.9× | 42.9× |
| Insider trades, last 12 months | sold $10.2 million | sold $9.8 million |
| Piotroski F-score | — | 7 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
AlkermesAmneal Pharmaceuticals
Operating margin
Percent of revenue
AlkermesAmneal Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AlkermesAmneal Pharmaceuticals
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Alkermes and Amneal Pharmaceuticals pages.